Back to Search Start Over

Why lithium should be used in patients with bipolar disorder? A scoping review and an expert opinion paper

Authors :
Gaia Sampogna
Delfina Janiri
Umberto Albert
Filippo Caraci
Giovanni Martinotti
Gianluca Serafini
Alfonso Tortorella
Alessandro Zuddas
Gabriele Sani
Andrea Fiorillo
Sampogna, Gaia
Janiri, Delfina
Albert, Umberto
Caraci, Filippo
Martinotti, Giovanni
Serafini, Gianluca
Tortorella, Alfonso
Zuddas, Alessandro
Sani, Gabriele
Fiorillo, Andrea
Source :
Expert Review of Neurotherapeutics. 22:923-934
Publication Year :
2022
Publisher :
Informa UK Limited, 2022.

Abstract

Introduction: Lithium treatment is considered the gold standard for the long-term management of bipolar disorder and recurrent unipolar depression. It is also extremely effective in other psychiatric conditions characterized by impulsivity and aggression, and for the prevention of suicidal behaviours. Areas covered: This paper provides a scoping review and an expert commentary regarding the use of lithium in adult patients. Available information about efficacy, tolerability, dosing, and switching is analyzed, and the strategies that may be most useful in real-world clinical settings are highlighted. Expert opinion: Lithium is effective on different domains of bipolar disorder, including the long-term prevention of recurrences of affective episodes, management of acute mania as well as in the prophylaxis of all affective episodes. Lithium has been defined a 'forgotten drug,' since its use in routine clinical practice has been declined over the last 20 or 30years. Reasons for this trend include lack of adequate training on the management of lithium side effects. Considering its efficacy, use of lithium in ordinary clinical practice should be promoted. Several strategies, such as using slow-release formulations, can be easily implemented in order to minimize lithium side effects and improve its tolerability profile.

Details

ISSN :
17448360 and 14737175
Volume :
22
Database :
OpenAIRE
Journal :
Expert Review of Neurotherapeutics
Accession number :
edsair.doi.dedup.....6f2cdc6d66af7ec82188177f2a8e98c6
Full Text :
https://doi.org/10.1080/14737175.2022.2161895